Bachem Appears in 85.1% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide API Manufacturing. For more detail, you can also read Peptide API Manufacturing: AI Visibility Discovery Index.
On this report
Browse sections
- Answer Capsule
- Current AI visibility
- What changed since last month
- Next Step
- Step 1. Measure
- Step 2. Make the website consistent
- Step 3. Align the external narrative
- Step 4. Optimize priority company pages
- Step 5. Publish around buyer questions
- Our 90-day action plan
- Methodology
- Our first three priorities
- Related research
- Learn More
Key Takeaways
- Bachem appeared in 258 of 303 benchmark answers and was recommended in 173, making it the most visible company in the set.
- The main verification issue is a high-priority conflict about who can buy, alongside a smaller dispute over revenue and scale figures.
- Several third-party pages and Bachem website pages were cited in the answers, but each source still needs independent fact-checking before any correction request.
- The 90-day plan focuses on baseline measurement, verified page updates, publisher requests, and content briefs built around buyer questions about peptide suppliers.
Answer Capsule
In November 2026, Bachem appeared in 258 of 303 AI answers included in the Peptide API Manufacturing benchmark (85.15%). It received 173 recommendations (57.10%), with 152 Top 3 placements and 113 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.
Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. This edition establishes a research baseline. It does not claim a change from earlier editions measured on a different basis. Conflicting AI claims require verification before corrections are proposed.
Current AI visibility
Questions This Section Answers
- How do Bachem mentions, recommendations and placements compare with its Peptide API Manufacturing peers?
Bachem recorded 258 mentions (85.15%) and 173 recommendations (57.10%) across 303 answers included in the benchmark. Top 3 placements numbered 152; first-place recommendations numbered 113. Framing among its mentions was 194 positive, 64 neutral and 0 negative.
Rank | Company | Mentions | Mention rate | Recommendations | Recommendation rate | Top 3 | Top 3 rate | #1 | #1 rate |
|---|---|---|---|---|---|---|---|---|---|
1 | Bachem | 258 | 85.15% | 173 | 57.10% | 152 | 50.17% | 113 | 37.29% |
2 | AmbioPharm | 110 | 36.30% | 82 | 27.06% | 63 | 20.79% | 8 | 2.64% |
3 | Biosynth Peptide Division | 71 | 23.43% | 63 | 20.79% | 42 | 13.86% | 6 | 1.98% |
4 | PolyPeptide Group | 70 | 23.10% | 46 | 15.18% | 34 | 11.22% | 1 | 0.33% |
5 | CPC Scientific | 53 | 17.49% | 32 | 10.56% | 18 | 5.94% | 3 | 0.99% |
6 | CordenPharma Peptides | 49 | 16.17% | 21 | 6.93% | 16 | 5.28% | 1 | 0.33% |
7 | CSBio | 8 | 2.64% | 6 | 1.98% | 0 | 0.00% | 0 | 0.00% |
Bachem is the company most often named in this benchmark, and most of those appearances also carry an endorsement. That combination of reach and approval is the strongest position in the set, and it is the asset the work below should protect rather than rebuild.
The gap to the next company is wide on every measure, so the practical question is not how to gain ground but how to keep the position credible. Positive framing dominates its mentions, with no negative wording recorded. That is a reputation worth defending with verified facts, because a single disputed claim can travel further than a strong average.
We would treat the current standing as a baseline to be checked, not a result to be celebrated. The first task is confirming which claims behind these answers are accurate, so the visibility rests on evidence the company can stand behind.
What changed since last month
Questions This Section Answers
- How did Bachem counts and coverage differ across the available monthly snapshots?
Metric | Nov 2026 |
|---|---|
Mentions | 258 / 303 (85.15%) |
Recommendations | 173 / 303 (57.10%) |
Top 3 recommendations | 152 / 303 (50.17%) |
#1 recommendations | 113 / 303 (37.29%) |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
This edition is the first broad baseline, built from a wider set of questions than earlier editions. The earlier figures stay in the archive but are not a like-for-like comparison, so no movement should be read into the difference between them and this month.
That matters for how the client uses the report. The current position is a starting reference point, and future editions screened the same way can be compared against it. Until then, month-to-month changes in answer totals should be read as separate samples rather than as a trend.
We would set expectations accordingly: the value this month is a reliable starting picture, and the value in later months comes from repeating the same screening so any change is meaningful.
AI recommendation trend
Observed recommendation rate (%), Nov 2026
- Bachemno changeNov 202657.10%
Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.
/ Take the next step
Want to Understand Your AI Citation Footprint?
We start every engagement with a full audit of how AI systems reference your brand today.
Measurable, Repeatable Programme
Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge
Citation Architecture Review
Identify which high-authority community sources are and aren't working in your favour across AI platforms.
AI Visibility Audit
Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.
Step 1. Measure
Questions This Section Answers
- What should the agency measure and verify first for Bachem?
AI answers contained 13 conflicting claims about Bachem: 0 critical, 9 high, 1 medium, 3 low. Of these, 9 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
The answers contained a cluster of conflicting claims about Bachem, and most were rated high priority for checking. Those ratings are a triage tool, not a finding that anyone made a mistake. They tell the client where a wrong impression would do the most damage if it turned out to be inaccurate.
A visibility comparison would show where Bachem leads and where rivals appear alongside it, which helps decide how much effort each claim deserves. A fact-check list would then assign each disputed point to someone who can confirm it against primary sources.
We would deliver both as working documents: a scorecard for the competitive picture and a claim list with owners and evidence requirements, so the client can act on the highest-priority items first.
Step 2. Make the website consistent
Questions This Section Answers
- Which recorded claim differences about Bachem should be verified before proposed page edits?
Review topic | Severity | Recorded AI claim A | Recorded AI claim B |
|---|---|---|---|
peptide revenue / scale | medium | CHF 605M peptide API revenue | CHF 695.1 million in 2025 group sales |
who can buy (eligibility) | high | B2B/institutional only; not individual consumers | anyone can buy online directly |
who can buy (eligibility) | high | B2B/institutional only; not individual consumers | anyone can buy online directly |
who can buy (eligibility) | high | B2B/institutional only; not individual consumers | anyone can buy online directly |
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Two topics account for the disputed claims: how large the peptide business is, and who is eligible to buy. The eligibility question is the more serious, because a claim that anyone can buy online directly conflicts with a business-to-business positioning and could mislead the wrong audience.
The revenue and scale conflict may simply reflect different reporting periods or different measures, so the entity and date need resolving before anyone treats it as an error. We would not decide which answer is right from the report alone.
Our proposal is a verification pass against current primary sources, followed by page briefs only where the confirmed facts show a gap. Where the sources support the existing position, the outcome is a documented no-change decision rather than an edit.
Step 3. Align the external narrative
Questions This Section Answers
- Which cited third-party pages are relevant to fact review for Bachem?
Cited page selected for review | Citation appearances in all captured answers | Answers mentioning the company | Conflicting claims linked to this page |
|---|---|---|---|
https://alibaba.com/supplier/bachem-peptides.html | 1 | 1 | 3 |
https://bioscience.co.uk/userfiles/pdf/Bachem%20Catalog_and_Custom_Peptides.pdf | 1 | 1 | 3 |
https://clinicaltrialsarena.com/contractors/water-purification/bachem/ | 1 | 1 | 3 |
https://peptidecompass.net/vendors/bachem-americas | 1 | 1 | 3 |
https://peptiderecon.com/suppliers/pharmaceutical/bachem | 1 | 1 | 3 |
https://peptidex.ai/sourcing/cdmo/bachem | 1 | 1 | 3 |
These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.
Several third-party pages were cited alongside the disputed claims, including supplier directories, a catalog PDF and contractor listings. Being cited next to a conflict does not make a page the cause, and the same answer can touch more than one source. Each page needs its current contents checked before any request is considered.
We would review the selected pages for accuracy about Bachem and separate genuine errors from outdated or ambiguous wording. Only where a clear, verifiable inaccuracy is found would we prepare an evidence-backed request to the publisher.
Requests would be framed as corrections with supporting sources, and responses recorded whether or not a change follows. Pages that cannot be confidently matched to the company stay out of the queue.
Step 4. Optimize priority company pages
Questions This Section Answers
- Which observed Bachem website pages should receive review briefs?
Company website page | Citation appearances in all captured answers | Benchmark answers citing the page | Recommending answers citing the page |
|---|---|---|---|
https://bachem.com/ | 99 | 95 | 73 |
https://shop.bachem.com/ | 58 | 44 | 30 |
https://bachem.com/about-bachem/ | 8 | 8 | 0 |
https://bachem.com/knowledge-center/what-are-apis-in-pharmaceutical-manufacturing/ | 6 | 6 | 1 |
https://bachem.com/custom-peptide-synthesis-services/ | 5 | 5 | 3 |
https://bachem.com/knowledge-center/peptide-manufacturing-step-by-step-guide/ | 5 | 5 | 1 |
https://bachem.com/knowledge-center/what-is-a-cdmo-why-might-you-need-one/ | 5 | 5 | 1 |
https://bachem.com/knowledge-center/faq-frequently-asked-questions/ | 4 | 4 | 0 |
The company's website was cited 248 times across 44 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.
The company website is by far the most cited source in the answers, with the homepage and shop carrying most of that weight. The knowledge-center pages appear far less often, and some were cited in answers that did not recommend the company. That pattern suggests the core commercial pages do the heavy lifting while supporting content plays a smaller role.
We would build page briefs for the priority pages using approved facts and the questions buyers actually ask, starting with the homepage and shop where citation volume is highest. Each brief would state which confirmed facts it relies on and which audience question it answers.
Briefs would be proposed work, reviewed by the client before any change, and would not assume the current pages are wrong.
Step 5. Publish around buyer questions
Questions This Section Answers
- Which observed buyer questions support content briefs for Bachem?
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the biggest peptide companies? | 5 | 5 | 4 |
What companies sell the most peptides? | 5 | 5 | 4 |
What are the best peptide companies in the US? | 4 | 4 | 4 |
What company makes the best peptides? | 4 | 4 | 4 |
What is the most legit peptide company? | 4 | 4 | 4 |
What is the reputable company for peptides? | 4 | 4 | 4 |
What is the best peptide company in the USA? | 3 | 3 | 3 |
What is the best peptide company out there? | 3 | 3 | 3 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
The recorded questions are almost all about which peptide companies are the biggest, best or most reputable. Bachem appears in every one of these answers and is recommended in nearly all of them, which shows the company is already part of the shortlist conversation.
That makes buyer-question content a defensive play: reinforce the reasons a buyer should trust Bachem when the question is framed around reputation and legitimacy. The eligibility confusion found elsewhere makes clear, accurate purchasing information especially valuable here.
We would check existing coverage first, then draft briefs for content that answers these questions directly with approved facts, rather than creating new pages by default.
Our 90-day action plan
Questions This Section Answers
- How should the agency sequence the proposed Bachem work and judge completion?
Period | Deliverable | Completion criterion |
|---|---|---|
Days 1–30 | Baseline scorecard, scoped fact-review register and page/source shortlist | Each record has an owner, evidence requirement and review status |
Days 31–60 | Approved page briefs and justified publisher requests | Separate confirmed edits, no-change decisions, requests and responses |
Days 61–90 | Buyer-content briefs and a fresh scorecard | Record work completed separately from measured answer outcomes and comparability limits |
The first month produces the working foundation: a baseline scorecard, a scoped fact-review register and a shortlist of pages and sources. Each record gets an owner, an evidence requirement and a review status, so nothing sits unresolved without a reason.
The second month turns confirmed findings into approved page briefs and justified publisher requests, with confirmed edits, no-change decisions, requests and responses kept separate. The third month adds buyer-content briefs and a fresh scorecard.
Completed work will be reported separately from measured answer outcomes. Delivering briefs and requests does not guarantee a change in visibility, and the plan is built so the client can see what was done apart from what the answers later show.
Methodology
Questions This Section Answers
- How are Bachem answer metrics and citation populations defined?
This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 303 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.
An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.
The wider citation analysis covers 359 captured answers and 2381 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Nov 2026 | 303 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.
Future editions using the same screening scope can be compared against this baseline.
The answers behind these figures were collected on dates that have not been verified, and the rates rest on the answers that met the benchmark's inclusion rules. A company counts as recommended only when an answer endorses it with positive wording, and top-three and first-place counts sit inside those recommendations rather than adding to them.
Because one answer can name several companies, company counts cannot be summed to find a number of distinct answers. Sentiment describes answer wording, not customer satisfaction. The wider citation analysis covers more answers than the benchmark, and cited pages still need independent checking.
Earlier editions used a narrower question set, so this edition is a new baseline rather than a trend.
Our first three priorities
The first priority is resolving the eligibility conflict, since a claim that anyone can buy directly is the one most likely to mislead the wrong audience and the one where verified facts would do the most good. The second is confirming the scale and revenue figures, separating genuine error from different reporting periods before any correction is considered.
The third is turning the buyer questions into content briefs that reinforce Bachem's reputation where it already appears, using approved facts and checking existing coverage first. Together these protect a leading position by making sure the answers rest on evidence the company can defend.
Related research
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide API Manufacturing. For more detail, you can also read Peptide API Manufacturing: AI Visibility Discovery Index.
/ Learn More
Understanding AI search visibility.
AI search experiences create answers by pulling information from many places online and summarizing it into a single response.


